VanEck Junior Gold Miners vs Viatris Inc — how do they compare? VanEck Junior Gold Miners trades at $114.61 (market cap $8.22B), while Viatris Inc trades at $17.62 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2.4× VanEck Junior Gold Miners's market cap, and Viatris Inc pays a 2.75% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Viatris Inc for 57 Days on average.
| GDXJ | VTRS | |
|---|---|---|
Market Cap | $8.22B | $20.03B |
Volume | 3,212,198 | 14,109,977 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $18.27 |
52-Week Low | $87.56 | $9.74 |
Typical Hold Time | 41 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $113.02, up 3.56% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF is undergoing significant rebalancing, with multiple junior mining companies added in September 2026, potentially increasing diversification. Key support lies at $110, with resistance at $113. Financial ratios are not applicable as this is a fund tracking an index of gold mining equities.
The outlook remains cautious due to bearish technicals, though inclusion of new holdings may attract flows. Risks include gold price volatility and mining sector operational challenges. Analyst views on constituent stocks vary, but the ETF offers exposure to small-cap gold miners, which can be high-risk, high-reward during gold rallies.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →